PUBLIC DISCLOSURE & CLARIFICATION

BioGlyco supplement products (including BioGlyco Flow, BioGlyco Capsules, and BioGlyco Blood) are not affiliated with CD BioGlyco.

CD BioGlyco does not manufacture, distribute, or provide after-sales support for these consumer products. For any product-related questions, please contact the original seller directly.

Carbohydrate-based Glycomedicine Development Platform

Home
Platforms
Carbohydrate-based Glycomedicine Development Platform

Inquiry

Carbohydrate-based Glycomedicine Development Platform

Inquiry

CD BioGlyco is a leader in the field of glycomedicine development. Our team has developed a comprehensive glycomedicine development platform focused on solving difficulties and problems in glycomedicine research and development. We are confident to be your indispensable research assistant in the field of glycobiology.

According to the sources of carbohydrates, our services include plant-derived, animal-derived, microbial-derived, and synthetic carbohydrate-based glycomedicine development. Depending on the types of carbohydrates, our services include monosaccharide, disaccharide, trisaccharide, oligosaccharide, polysaccharide, glycoside, and glycopeptide-based glycomedicine development. Depending on the applications, we offer the development of anticoagulant, cardiovascular, antitumor, antidiabetic, antibacterial, antiviral, and antiparasitic glycomedicines. According to the strategies, we develop glycomedicine targeting the interaction of lectins and carbohydrates, targeting carbohydrates of specific pathogens, or targeting carbohydrate changes in diseases.

In addition, we also provide glycoengineering-based protein and antibody drug development services for global customers.

By Source

Plant-derived Carbohydrate-based Glycomedicine Development

We provide isolation, purification, and characterization services of plant-derived carbohydrates, which are the basis for the development of plant-derived glycomedicine with tailored biological functions.

Animal-derived Carbohydrate-based Glycomedicine Development

CD BioGlyco has accomulated extensive experience in modifing the polysaccharide groups of animal-derived carbohydrates such as chitosan, chondroitin, and hyaluronic acid to develop glycomedicine.

Microbial-derived Carbohydrate-based Glycomedicine Development

CD BioGlyco has developed various strategies for microbial-derived carbohydrate-based glycomedicine development, such as designing targeted block copolymers containing microbially derived carbohydrates.

Synthetic Carbohydrate-based Glycomedicine Development

CD BioGlyco has developed many methods including enzymatic and chemical modifications to meet customers' needs for the development of synthetic carbohydrate-based glycomedicines.

By Type

Monosaccharide-based Glycomedicine Development

Monosaccharides are important metabolic intermediates and biomarkers. CD BioGlyco has established a specialized platform for the development of monosaccharide-based glycomedicines.

Disaccharide-based Glycomedicine Development

CD BioGlyco has been focusing on the glycomedicine research for many years, providing customers with the design and synthesis services of disaccharide-based glycomedicine.

Trisaccharide-based Glycomedicine Development

CD BioGlyco has a professional and first-class research team to help solve customers' problems in the development of trisaccharide-based glycomedicine.

Oligosaccharide-based Glycomedicine Development

CD BioGlyco designs glycomedicine according to each specific customers' requirement, and chemically or enzymatically synthesizes well-defined oligosaccharides and performs structural analysis.

Polysaccharide-based Glycomedicine Development

As a leading provider in the field of glycobiology, CD BioGlyco offers chemical and enzymatic modification of natural polysaccharides as well as customization services of non-natural polysaccharide analogs.

Glycoside-based Glycomedicine Development

CD BioGlyco provides glycosides-based glycomedicine development services, such as chemical synthesis of natural glycosides and their artificial analogs, and determination of glycoside activity.

Glycopeptide-based Glycomedicine Development

CD BioGlyco has developed a special platform for glycomedicine based on N-glycopeptide and O-glycopeptide to solve the problems and difficulties encountered by customers in the development.

Glycomimetic-based Glycomedicine Development

We will design and synthesize glycomimetic-based glycomedicine to improve drug absorption, distribution, metabolism and excretion.

By Application

Carbohydrate-based Anticoagulant Glycomedicine Development

CD BioGlyco has one-stop services for the synthesis, modification, analysis, and activity detection of carbohydrate-based anticoagulants glycomedicines. Welcome global researchers to cooperate with us!

Carbohydrate-based Cardiovascular Glycomedicine Development

CD BioGlyco provides carbohydrate-based cardiovascular glycomedicine development and activity determination services for our clients worldwide. Welcome global researchers to cooperate with us!

Carbohydrate-based Antitumor Glycomedicine Development

The professional team and experienced scientists of CD BioGlyco provide global customers with in vitro and in vivo antitumor activity screening services of glycomedicine.

Carbohydrate-based Antidiabetic Glycomedicine Development

As a leader in the field of glycomedicine, CD BioGlyco not only customizes the development of carbohydrate-based antidiabetic glycomedicine for customers, but also helps customers evaluate the activity of glycomedicines.

Carbohydrate-based Antibacterial Glycomedicine Development

CD BioGlyco provides synthesis and antibacterial activity testing services for aminoglycosides, nucleosides, macrolides and glycopeptides based antibacterial glycomedicines.

Carbohydrate-based Antiviral Glycomedicine Development

CD BioGlyco provides carbohydrate modification, carbohydrate-based antiviral glycomedicine synthesis, and antiviral glycomedicine bioactivity screening services.

Carbohydrate-based Antiparasiti Glycomedicine Development

We provide comprehensive services for the development of carbohydrate-based antiparasiti glycomedicines, such as synthetic carbohydrate-based antiparasiti glycomedicines and screening of antiparasitic activities.

By Discovery Strategy

Targeting Carbohydrate-Lectin Interactions

According to the needs of customers, we develop glycomedicines with high inhibitory activity on the interaction between carbohydrates and lectins.

Targeting Carbohydrates of Pathogens

Since the microbes that cause infections often contain different carbohydrates than humans, it is needed to develop glycomedicines specifically targeting carbohydrates of different pathogens.

Targeting Disease-related Changes in Carbohydrates

The levels of carbohydrates vary with the onset of various diseases. We provide glycomedicine development services for global clients according to the relevant changes of different diseases.

Glycoengineering-based Glycomedicine Development

In recent years, more and more researchers have utilized the function of carbohydrates to develop biopharmaceuticals. CD BioGlyco develops protein and antibody drugs by modifying carbohydrates with Glycoengineering methods.

CD BioGlyco is committed to providing high-quality carbohydrate-based glycomedicine development services. If you have special needs in glycomedicine development, please feel free to contact us for more information.

References:

Ernst, B.; Magnani, J.L. From carbohydrate leads to glycomimetic drugs. Nature reviews drug discovery. 2009, 8(8): 661-677.
Kondo, H. Novel approaches for glycodrug discovery. Glycoscience. 2008.

This service is for Research Use Only, not intended for any clinical use.

Quick Links